Journal of Infectious Diseases and Medical Microbiology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44 7460731551

Through personalized antimicrobial therapy, Detection and assessing AmpC beta lactamase types in Escherichia coli and Klebsiella pneumonia in Egyptian hospitals

Joint Event on Global Experts Meeting on STD-AIDS and Infectious Diseases & 12th International Conference on Allergy, Immunology and Rheumatology
November 21-22, 2019 | Singapore

Naiven Helmy

National Research Center, Egypt

Keynote : J Infectious Disease Med Microbiol


Microorganisms existed on this earth millions of years before the evolution of man. Beta-lactamase production is the most common mechanism of resistance in Gram negative bacteria. They are of significant concern because they restrict therapeutic options, cause treatment failures and are increasing in occurrence worldwide. Amp C betalactamase are Ambler class C or group I cephalosporinases that confer resistance to cephalosporins and cephamycins and are not affected by inhibitors (clavulanic acid, tazobactam and sulbactam).We are seeking effective prevention and detection of an ever- increasing range of infection by multiple drug resistance bacteria and combating antimicrobial resiatance including antibiotic resistance

In our study we determined the occurrence of chromosomal and plasmid mediated β-lactamases (AmpC) gene. In addition we evaluated the Prevalence of plasmid Amp C beta-lactamases in E. coli and Klebsiella pneumoniae to find its burden on Egyptian community. We compared the performance of the phenotypic tests with polymerase chain reaction (PCR) to reach the most convenient method of detection without compromising accuracy and precision. In the attempts of personalized anti-microbial therapy, we assessed the prevalence of DHA resistant strain of betalactamase resistance in Egypt and detecting its mutational sequence.


Naiven Helmy is currently working as a Consultant of clinical microbiology and immunology, Researcher at clinical and chemical pathology department, National research center,Egypt. Member of molecular laboratory center of excellence, National research Centre. Working in one of private megalabs (El mokhtaber laboratory in Egypt) as clinical microbiologist. Shared in several internationally funded community projects as Alleviating and Managing Anemia induced Therapy for Hepatitis C Patients Title: in Seven Villages of Egypt/ Community outreach approach for having a model of a village controlled from diabetes with improved quality of life: Egypt. Has 13 ongoing projects dealing with genetic background of high socially – economic burden infectious and chronic disease with many published scientific publications in well acclaimed journals.

E-mail: naivenhelm[email protected]

Get the App